EpiVax unveils a new vaccine

EpiVax Inc., a Providence-based biotechnology firm, last week announced it has developed a promising vaccine against tularemia. In animal studies at Rhode Island Hospital, the firm said, its TuliVaxTM protected against lethal doses of the disease. Stephen Gregory, an associate professor at Brown University's School of Medicine, used mice with "humanized" immune systems; the mice…